Results 51 to 60 of about 8,424 (263)

Randomized Comparison of Eptifibatide Versus Abciximab in Primary Percutaneous Coronary Intervention in Patients With Acute ST-Segment Elevation Myocardial Infarction Results of the EVA-AMI Trial [PDF]

, 2010
ObjectivesThe aim of this study was to compare eptifibatide and abciximab as adjuncts to primary percutaneous coronary intervention (PCI).BackgroundThe glycoprotein (GP) IIb/IIIa receptor inhibitor abciximab as adjunct to primary PCI in patients with ST ...
Banik, Norbert, Bode, Christoph, Bourkaib, Ryad, Haude, Michael, Heuer, Hubertus, Kropff, Stefan, Lablanche, Jean-Marc, Margenet, Alain, Schröder, Rolf, Teiger, Emmanuel, Zahn, Ralf, Zeymer, Uwe   +11 more
core   +1 more source

Efficacy of intravenous eptifibatide in primary percutaneous coronary intervention patients

Journal of Medicine and Life, 2021
Early and complete restoration of blood flow in closed coronary arteries is the main goal in treating patients with myocardial infarction. Primary angioplasty is not always successful in establishing myocardial blood flow. Although the strategy of adding
R. Jalalian, S. Golshani, Hossein Farsavian, Mahsa Vatani, A. Farsavian   +4 more
semanticscholar   +1 more source

Association of Ebtifibatide Administration Timing and TIMI Flow of Infarct Related Artery During Primary PCI

Majalah Kardiologi Indonesia, 2013
Background. Optimal administration timing of Glicoprotein IIb/IIIa inhibitor in STEMI patients undergoing Primary PCI is controversial. Several stud -ies have shown that early administration of eptifibatide, which is given to patients with pain awitan of
Abdul Hakim Alkatiri, Yoga Yuniadi, Dicky A Hanafy, Doni Firman, Sunarya Soerianata   +4 more
doaj   +1 more source

Stroke in Patients With Acute Coronary Syndromes: Incidence and Outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial [PDF]

, 1999
BACKGROUND: The incidence of stroke in patients with acute coronary syndromes has not been clearly defined because few trials in this patient population have been large enough to provide stable estimates of stroke rates.
Alberts, M.J., Berdan, L.G. (Lisa), Califf, R.M. (Robert), Deckers, J.W. (Jaap), Graffagnino, C. (Carmen), Granger, C.B. (Christopher), Harrington, R.A. (Robert Alex), Laskowitz, D.T., Lincoff, A.M. (Michael), MacAulay, C.M., Mahaffey, K.W. (Kenneth), Miller, J.M., Simoons, M.L. (Maarten), Sloan, M.A. (Michael), Topol, E.J. (Eric)   +14 more
core   +1 more source

How safe is eptifibatide during urgent carotid artery stenting?

Frontiers in Neurology, 2013
Background: Glycoprotein IIB/IIIA inhibitors are occasionally utilized during carotid artery stenting (CAS) in the presence or absence of a visualized intra-operative thrombus. Objective: We assess the hemorrhagic and clinical outcomes associated with
Hesham eAllam, Nirav eVora, Randall eEdgell, Richard Charles Callison, Yasir eAl Khalili, Michelle eStorkan, Amer eAlshekhlee, Amer eAlshekhlee   +7 more
doaj   +1 more source

Platelet anesthesia with nitric oxide with or without eptifibatide during cardiopulmonary bypass in baboons [PDF]

, 1999
Objective:This study tested the hypothesis that nitric oxide or nitric oxide and eptifibatide (Integrilin) reversibly inhibit platelet activation and consumption during cardiopulmonary bypass and rapidly restore platelet numbers and function after bypass.
Edmunds, L.Henry, Hanson, C.William, Malekan, Ramin, Niewiarowski, Stefan, Rao, A.Koneti, Sun, Ling, Suzuki, Yasuyuki   +6 more
core   +1 more source

Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundIn patients with non‐ST‐segment elevation acute coronary syndromes, inhibition of platelet aggregation (IPA) with a potent P2Y12 inhibitor, ticagrelor, was inferior to tirofiban infusion at 2 hours, indicating that glycoprotein IIb/IIIa ...
Moazez J. Marian, Oluseun Alli, Firas Al Solaiman, Brigitta C. Brott, Mark Sasse, Tara Leesar, Sumanth D. Prabhu, Massoud A. Leesar   +7 more
doaj   +1 more source

Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study [PDF]

, 2002
ObjectivesThe study was done to determine whether eptifibatide, a platelet glycoprotein (GP) IIb/IIIa antagonist, prevents ischemic complications following percutaneous coronary interventions (PCIs) in women as well as in men.BackgroundEptifibatide ...
Berdan, Lisa G, Fernandes, Laura S, Hochman, Judith S, Joseph, Diane, Kilaru, Rakhi, Kleiman, Neal S, Lorenz, Todd J, Madan, Mina, Mann, Tift, Maresh, Kelly J, O’Shea, J.Conor, Pacchiana, Cindy, Tcheng, James E, Weiner, Bonnie   +13 more
core   +1 more source

Corrections to “An Optimized Safe Process from Bench to Pilot cGMP Production of API Eptifibatide Using a Multigram-Scale Microwave-Assisted Solid-Phase Peptide Synthesizer”

Organic Process Research & Development, 2021
[This corrects the article DOI: 10.1021/acs.oprd.1c00368.].
Annunziata D’Ercole, L. Pacini, G. Sabatino, M. Zini, L. Milli, F. Nuti, A. Ribecai, A. Paio, P. Rovero, A. Papini   +9 more
semanticscholar   +1 more source

Cryo-EM structures of full-length integrin αIIbβ3 in native lipids

Nature Communications, 2023
Platelet integrin αIIbβ3 is maintained in a bent inactive state (low affinity to physiologic ligand), but can rapidly switch to a ligand-competent (high-affinity) state in response to intracellular signals (“inside-out” activation).
Brian D. Adair, Jian-Ping Xiong, Mark Yeager, M. Amin Arnaout   +3 more
doaj   +1 more source